Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ADH1B | P00325 | 2/20 | 0.39 |
| ▸ | ADH1C | P00326 | 2/20 | 0.39 |
| ▸ | ADH1A | P07327 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061687 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| SCHEMBL28444462 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| SCHEMBL27634237 | 0.75 | — | — | |
| SCHEMBL5372240 | 0.75 | — | — | |
| SCHEMBL21958304 | 0.75 | ALDH1A1 (0.45) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| SCHEMBL21567116 | 0.75 | ALDH1A1 (0.45) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| SCHEMBL21958303 | 0.75 | ALDH1A1 (0.45) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| SCHEMBL7648803 | 0.75 | ALDH1A1 (0.39) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| SCHEMBL8712048 | 0.73 | ALDH1A1 (0.43) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 | |
| Hydrochloric Acid SCHEMBL4048732 | 0.73 | ALDH1A1 (0.43) | ALDH1A1HSD17B10EPHX1CYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12004868-B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | SIGNPATH PHARMA INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4234037-A2 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | Signpath Pharma, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116265435-A | Hydrogenation method of olefin compounds | 台州学院 | 2023-06-20 | — | — | CN | disclosed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3082768-B1 | LIPOSOMAL MITIGATION OF DRUG-INDUCED INHIBITION OF THE CARDIAC IKR CHANNEL | SIGNPATH PHARMA INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3326616-B1 | LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT | SIGNPATH PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3697386-A2 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | Signpath Pharma, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-111481508-A | Protective compositions and methods for agents causing ion channel disease | 萨恩帕斯药物有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-10617639-B2 | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | SIGNPATH PHARMA, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| WO-2004098525-A3 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP (CA) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| WO-2005018635-A2 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2005-03-03 | — | — | WO | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
| WO-2004098525-A9 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP (CA) | 2005-01-20 | — | — | WO | disclosed |
| CN-1180127-C | Corrosion inhibiting additive for cosmetic products | — | 2004-12-15 | — | — | CN | disclosed |
| WO-2004098525-A2 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2004-11-18 | — | — | WO | disclosed |
| CN-1409775-A | Corrosion inhibiting additive for cosmetic products | UNILEVER PLC (NL) | 2003-04-09 | — | — | CN | disclosed |
| CN-1006401-B | Process for preparing inositol triphosphate | SIREN MATTI (CH) | 1990-01-10 | — | — | CN | disclosed |
| CN-85109110-A | Process for the preparation of inositol triphosphate and compositions thereof | — | 1986-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | ALDH1A1 3254/4885HSD17B10 3241/4885EPHX1 595/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | ALDH1A1 2775/4885HSD17B10 3064/4885EPHX1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.